Add to a list

Inactive Instrument

Seagen Inc. Stock

SGEN

US81181C1045

Biotechnology & Medical Research

Analysts' recommendations: Seagen Inc.

23-12-15	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
23-03-24	Berenberg Bank Downgrades Seagen to Hold From Buy, Adjusts Price Target to $229 From $170	MT
23-03-21	TD Cowen Raises Price Target on Seagen to $229 From $145, Maintains Market Perform Rating	MT
23-03-20	Truist Securities Adjusts Price Target on Seagen to $229 From $152, Maintains Hold Rating	MT
23-03-15	Morgan Stanley Downgrades Seagen to Equalweight From Overweight, Adjusts Price Target to $229 From $173	MT

More recommendations

News in other languages: Seagen Inc.

24-02-05	Übernahmegerüchte schicken Morphosys auf Hoch seit Juli 2021
23-12-15	Pfizer, Inc: un ciclo per niente?
23-12-15	Pfizer : le dividende augmente, le titre rebondit
23-12-15	ÜBERBLICK/Anstehende Indexänderungen
23-12-14	Pfizer, Inc.: een cyclus voor niets?

More news

Managers and Directors: Seagen Inc.

Manager	Title	Age	Since
Chris Boshoff PSD	President	-	2023-12-13
Peggy Pinkston IRC	Investor Relations Contact	-	-

Director	Title	Age	Since
Deborah Baron BRD	Director/Board Member	57	2023-12-13
Alison Marquez O'Neill BRD	Director/Board Member	-	2023-12-13

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEAGEN INC.	-0.07%	+4.77%	-	-	43.15B
LONZA GROUP AG	+1.70%	+7.41%	+2.50%	+8.18%	49.92B
REVOLUTION MEDICINES, INC.	+0.92%	+3.93%	+399.71%	+604.02%	40.23B
IQVIA HOLDINGS INC.	+1.89%	+8.32%	+26.06%	-6.27%	34.55B
BEONE MEDICINES AG	+2.38%	+6.35%	+21.25%	+55.45%	33.09B
CELLTRION, INC.	+3.96%	+10.67%	+8.30%	+37.95%	27.51B
ASCENDIS PHARMA A/S	+2.51%	+5.27%	-	-	17.05B
MEDPACE HOLDINGS, INC.	+2.58%	+5.79%	+73.44%	+135.37%	15.92B
EUROFINS SCIENTIFIC SE	+0.32%	+0.58%	+14.00%	+19.09%	13.86B
IONIS PHARMACEUTICALS, INC.	+3.30%	+0.76%	+90.23%	+93.88%	13.52B
Average	+1.95%	+5.82%	+79.44%	+118.46%	27.3B
Weighted average by Cap.	+1.75%	+6.53%	+90.20%	+135.87%

See all sector performances

Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).

Employees

3,256

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
SGEN Stock

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

24-05-16	Fitch Affirms and Withdraws Pfizer's Ratings; Outlook Stable	AQ
24-03-28	Pieris Pharmaceuticals Announces Strategy to Maximize Partnered Milestone and Royalty Potential	AQ
24-02-29	Seagen Requests Director Review Of Unpatentability Decision In Adcetris® Patent PGR	AQ
24-01-30	PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable	AQ
24-01-10	Fitch Affirms Pfizer's Long-Term IDR at 'A'; Outlook Stable	AQ

Date	Insider	Type	Main position	Quantity	% Market Cap.
23-12-13	Roger Dansey	Issuer sale	Chief Executive Officer	496,247	0.2630%
23-12-13	Nancy Simonian	Issuer sale	Director	127,934	0.0678%
23-12-13	John Orwin	Issuer sale	Director	97,934	0.0519%

Seagen Inc. Stock

Stocks

SGEN

US81181C1045

Biotechnology & Medical Research

Latest news : Seagen Inc.

Analysts' recommendations: Seagen Inc.

Press Releases: Seagen Inc.

News in other languages: Seagen Inc.

Quotes and Performance

Managers and Directors: Seagen Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

24-02-05	Takeover rumors send Morphosys to high since July 2021	DP
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Biotechnology Select Industry Index	CI
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P TMI Index	CI
23-12-18	Seagen Inc.(NasdaqGS:SGEN) dropped from S&P Global BMI Index	CI
23-12-15	Merck, Pfizer, Astellas Get FDA OK For Expanded Use Of Keytruda Plus Padcev	DJ
23-12-15	Pfizer: dividend increases, stock rebounds
23-12-15	Euphoria subsides for Triple-Witching Day
23-12-15	Analyst recommendations: Adobe, Blackrock, Roblox, Snap, US Bancorp...
23-12-15	HBM Holdings Unit Nona Biosciences Signs Licensing Deal with Seagen for Tumor Medication; Shares Fall 5%	MT
23-12-15	Seagen Inc.(NasdaqGM:SGEN) dropped from NASDAQ Biotechnology Index	CI
23-12-15	Seagen Inc.(NasdaqGS:SGEN) dropped from NASDAQ-100 Index	CI
23-12-15	Seagen Inc.(NasdaqGS:SGEN) dropped from FTSE All-World Index	CI
23-12-14	Pfizer, Inc: A cycle for nothing?